Eli Lilly & Co. (LLY)
1169.54
-6.56
(-0.56%)
USD |
NYSE |
Aug 28, 12:59
Eli Lilly Cash from Operations (Quarterly) : 10.69B for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 10.69B |
| March 31, 2026 | 5.333B |
| December 31, 2025 | 3.225B |
| September 30, 2025 | 8.836B |
| June 30, 2025 | 3.087B |
| March 31, 2025 | 1.666B |
| December 31, 2024 | 2.474B |
| September 30, 2024 | 3.712B |
| June 30, 2024 | 1.466B |
| March 31, 2024 | 1.166B |
| December 31, 2023 | -311.90M |
| September 30, 2023 | 2.190B |
| June 30, 2023 | 631.90M |
| March 31, 2023 | 1.731B |
| December 31, 2022 | 1.580B |
| September 30, 2022 | 2.185B |
| June 30, 2022 | 820.70M |
| March 31, 2022 | 2.499B |
| December 31, 2021 | 2.156B |
| September 30, 2021 | 1.631B |
| June 30, 2021 | 1.776B |
| March 31, 2021 | 1.697B |
| December 31, 2020 | 1.815B |
| September 30, 2020 | 1.807B |
| June 30, 2020 | 2.495B |
| Date | Value |
|---|---|
| March 31, 2020 | 382.40M |
| December 31, 2019 | 1.964B |
| September 30, 2019 | 1.510B |
| June 30, 2019 | 1.052B |
| March 31, 2019 | 311.30M |
| December 31, 2018 | 1.449B |
| September 30, 2018 | 2.122B |
| June 30, 2018 | 1.518B |
| March 31, 2018 | 436.50M |
| December 31, 2017 | 1.744B |
| September 30, 2017 | 1.881B |
| June 30, 2017 | 1.651B |
| March 31, 2017 | 339.90M |
| December 31, 2016 | 2.117B |
| September 30, 2016 | 1.659B |
| June 30, 2016 | 1.402B |
| March 31, 2016 | -326.90M |
| December 31, 2015 | 804.30M |
| September 30, 2015 | 1.105B |
| June 30, 2015 | 948.60M |
| March 31, 2015 | -84.80M |
| December 31, 2014 | 1.350B |
| September 30, 2014 | 1.691B |
| June 30, 2014 | 1.054B |
| March 31, 2014 | 272.30M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Johnson & Johnson | 8.616B |
| Merck & Co., Inc. | 5.37B |
| Pfizer Inc. | 835.00M |
| Bristol Myers Squibb Co. | 3.393B |
| Atai Beckley, Inc. | -35.09M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -15.40B |
| Cash from Financing (Quarterly) | 8.426B |
| Free Cash Flow | 13.56B |
| Free Cash Flow Per Share (Quarterly) | 5.007 |
| Free Cash Flow to Equity (Quarterly) | -7.063B |
| Free Cash Flow to Firm (Quarterly) | 4.685B |
| Free Cash Flow Yield | 1.28% |